Investigation of the Role of Interleukin 6 in Vitiligo Pathogenesis

References

• Aydıngöz IE, Kanmaz-Özer M, Gedikbaşi A, Vural P, Doğru-Abbasoğlu S, Uysal M. 2015. The combination of tumour necrosis factor-α −308A and interleukin-10 −1082G gene polymorphisms and increased serum levels of related cytokines: susceptibility to vitiligo. Clin Exp Dermatol. 40(1):71–77.
   PubMed Web of Science ®Google Scholar
• Cavalcanti NG, Marques CDL, Lins E Lins TU, Pereira MC, Rêgo MJBDM, Duarte ALBP, Pitta I da R, Pitta MGDR. 2016. Cytokine profile in gout: inflammation driven by IL-6 and IL-18? Immunol Invest. 45(5):383–95.
   PubMed Web of Science ®Google Scholar
• Deretzi G, Kountouras J, Koutlas E, Zavos C, Polyzos S, Rudolf J, Grigoriadis N, Gavalas E, Boziki M, Tsiptsios I. 2010. Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Mult Scler J. 16(9):1091–101.
   PubMed Web of Science ®Google Scholar
• Dubiński A, Zdrojewicz Z. 2007. The role of interleukin-6 in development and progression of atherosclerosis. Pol Merkur Lek. 22(130):291–94.
   Google Scholar
• Dwivedi M, Laddha NC, Arora P, Marfatia YS, Begum R. 2013a. Decreased regulatory T-cells and CD4 + /CD8 + ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res. 26(4):586–91.
   PubMed Web of Science ®Google Scholar
• Dwivedi M, Laddha NC, Begum R. 2013b. Correlation of increased MYG1 expression and its promoter polymorphism with disease progression and higher susceptibility in vitiligo patients. J Dermatol Sci. 71(3):195–202.
   PubMed Web of Science ®Google Scholar
• Dwivedi M, Laddha NC, Imran M, Shah BJ, Begum R. 2011. Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) in isolated vitiligo: a genotype-phenotype correlation. Pigment Cell Melanoma Res. 24(4):737–40.
   PubMed Web of Science ®Google Scholar
• Dwivedi M, Laddha NC, Mansuri MS, Marfatia YS, Begum R. 2013c. Association of NLRP1 genetic variants and mRNA overexpression with generalized vitiligo and disease activity in a Gujarat population. Brit J Dermatol. 169(5):1114–25.
   PubMed Web of Science ®Google Scholar
• Dwivedi M, Laddha NC, Shah K, Shah BJ, Begum R. 2013d. Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo. J Interf Cytokine Res. 33(11):646–59.
   PubMed Web of Science ®Google Scholar
• Dwivedi M, Laddha NC, Weetman AP, Begum R, Kemp EH. 2015. Vitiligo–A complex autoimmune skin depigmenting. autoimmunity: pathogenesis, clinical aspects and therapy of specific autoimmune diseases. Intech-Open. 153–74. doi:https://doi.org/10.5772/59762
   Google Scholar
• Farhan J, Al-Shobaili HA, Zafar U, Al Salloom A, Meki A-R, Rasheed Z. 2014. Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes. Br J Biomed Sci. 714:151–57. https://www.tandfonline.com/doi/full/10.1080/09674845.2014.11669980.
   PubMed Web of Science ®Google Scholar
• Fishman D, Faulds G, Jeffey R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic- onset juvenile chronic arthritis. J Clin Invest. 102(7):1369–76.
   PubMed Web of Science ®Google Scholar
• Giri PS, Dwivedi M, Begum R. 2020a. Decreased suppression of CD8+ and CD4+ T cells by peripheral regulatory T cells in generalized vitiligo due to reduced NFATC1 and FOXP3 proteins. Exp Dermatol. doi:https://doi.org/10.1111/exd.14157
   Google Scholar
• Giri PS, Dwivedi M, Laddha NC, Begum R, Bharti AH. 2020b. Altered expression of nuclear factor of activated T cells, forkhead box P3, and immune‐suppressive genes in regulatory T cells of generalized vitiligo patients. Pigment Cell Melanoma Res. 33(4):566–78.
   PubMed Web of Science ®Google Scholar
• Imokawa G. 2004. Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders. Pigment Cell Res. 17(2):96–110.
   PubMedGoogle Scholar
• Imran M, Laddha NC, Dwivedi M, Mansuri MS, Singh J, Rani R, Gokhale RS, Sharma VK, Marfatia YS, Begum R. 2012. Interleukin- 4 genetic variants correlate with its transcript and protein levels in patients with vitiligo. Br J Dermatol. 167(2):314–23. doi:https://doi.org/10.1111/j.1365-2133.2012.11000.x
   Google Scholar
• Jadeja SD, Mansuri MS, Singh M, Dwivedi M, Laddha NC, Begum R. 2017. A case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat. PLoS ONE. 12(7):e0180958.
   PubMed Web of Science ®Google Scholar
• Jadeja SD, Mansuri MS, Singh M, Patel H, Marfatia YS, Begum R. 2018. Association of elevated homocysteine levels and Methylenetetrahydrofolate reductase (MTHFR) 1298 A > C polymorphism with Vitiligo susceptibility in Gujarat. J Dermatol Sci. 90(2):112–22.
   PubMed Web of Science ®Google Scholar
• Jimbow K, Quevedo WC, Fitzpatrick TB, Szabo G. 1976. Some aspects of melanin biology: 1950–1975. J Invest Dermatol. 67(1):72–89.
   PubMed Web of Science ®Google Scholar
• Kamaraju AK, Bertolotto C, Chebath J, Revel M. 2002. Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by Interleukin-6 receptor signaling. J Biol Chem. 277(17):15132–41.
   PubMed Web of Science ®Google Scholar
• Kimura A, Kishimoto T. 2010. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 40(7):1830–35.
   PubMed Web of Science ®Google Scholar
• Kitamura R, Tsukamoto K, Harada K, Shimizu A, Shimada S, Kobayashi T, Imokawa G. 2004. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF‐M. J Pathol A J Pathol Soc Gt Britain Irel. 202(4):463–75.
   Google Scholar
• Kocer B, Nazliel B, Oztas M, Batur HZ. 2009. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report. Eur J Neurol. 16(4):e78–e79.
   PubMed Web of Science ®Google Scholar
• Kovacs D, Bastonini E, Ottaviani M, Cota C, Migliano E, Dell’Anna ML, Picardo M. 2018. Vitiligo skin: exploring the dermal compartment. J Invest Dermatol. 138(2):394–404.
   PubMed Web of Science ®Google Scholar
• Kristiansen OP, Mandrup-Poulsen T. 2005. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 54(Supplement 2):S114–S124.
   PubMed Web of Science ®Google Scholar
• Laddha NC, Dwivedi M, Begum R. 2012. Increased tumor necrosis factor (TNF) -α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. Ahmed N, editor. PLoS One. 7(12):e52298.
   PubMed Web of Science ®Google Scholar
• Laddha NC, Dwivedi M, Gani AR, Mansuri MS, Begum R. 2013c. Tumor necrosis factor B (TNFβ) genetic variants and its increased expression are associated with vitiligo susceptibility. PLoS ONE. 8(11):e81736.
   PubMed Web of Science ®Google Scholar
• Laddha NC, Dwivedi M, Gani AR, Shajil EM, Begum R. 2013a. Involvement of superoxide dismutase isoenzymes and their genetic variants in progression of and higher susceptibility to vitiligo. Free Radic Biol Med. 65:1110–25.
   PubMed Web of Science ®Google Scholar
• Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, Ramachandran AV, Dalai S, Begum R. 2013b. Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol. 22(4):245–50.
   PubMed Web of Science ®Google Scholar
• Laddha NC, Dwivedi M, Mansuri MS, Singh M, Gani AR, Yeola AP, Panchal VN, Khan F, Dave DJ, Patel A, et al. 2014a. Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol. 23(5):352–53.
   PubMed Web of Science ®Google Scholar
• Laddha NC, Dwivedi M, Mansuri MS, Singh M, Patel HH, Agarwal N, Shah AM, Begum R. 2014b. Association of Neuropeptide Y (NPY), Interleukin-1β (IL1β) Genetic Variants and correlation of IL1B transcript levels with vitiligo susceptibility. PLoS ONE. 9(9):e107020.
   PubMed Web of Science ®Google Scholar
• Lee A-Y, Kim N-H, Choi W-I, Youm Y-H. 2005. Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo. J Invest Dermatol. 124(5):976–83.
   PubMed Web of Science ®Google Scholar
• Liu J, Liao M-Q, Cao D-F, Yang Y, Yang Y, Liu Y-H, Zeng -F-F, Chen X-H. 2020. The association between interleukin-6 gene polymorphisms and risk of systemic lupus erythematosus: a meta-analysis with trial sequential analysis. Immunol Invest. 1–14. https://www.tandfonline.com/doi/full/10.1080/08820139.2020.1769646
   Google Scholar
• Mansuri MS, Jadeja SD, Singh M, Laddha NC, Dwivedi M, Begum R. 2017. The catalase gene promoter and 5ʹ-untranslated region variants lead to altered gene expression and enzyme activity in vitiligo. British Journal of Dermatology. 177(6):1590–600.
   PubMed Web of Science ®Google Scholar
• Mansuri MS, Laddha NC, Dwivedi M, Patel D, Alex T, Singh M, Singh DD, Begum R. 2016. Genetic variations (Arg5Pro and Leu6Pro) modulate the structure and activity of GPX1 and genetic risk for vitiligo. Exp Dermatol. 25(8):654–57.
   PubMed Web of Science ®Google Scholar
• Mansuri MS, Singh M, Jadeja SD, Begum R. 2019. Association of glucose 6-phosphate dehydrogenase (G6PD) 3ʹUTR polymorphism with vitiligo and in vitro studies on G6PD inhibition in melanocytes. J Dermatol Sci. 93(2):133–35.
   PubMed Web of Science ®Google Scholar
• Mansuri MS, Singh M, Jadeja SD, Gani AR, Patel R, Dwivedi M, Laddha NC, Ansarullah, Ramachandran AV, Begum R 2014. Could ER stress be a major link between oxidative stress and autoimmunity in vitiligo? Pigmentary Disorders. 1(123). doi:https://doi.org/10.4172/2376-0427.1000123
   Google Scholar
• Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. 2012. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci. 122(4):143–59.
   PubMed Web of Science ®Google Scholar
• Moretti S. 2002. Vitiligo and epidermal microenvironment: possible involvement of keratinocyte-derived cytokines. Arch Dermatol. 138(2):273–74.
   PubMedGoogle Scholar
• Moretti S, Fabbri P, Baroni G, Berti S, Ban D, Berti E, Nassini R, Lotti T, Massi D. 2009. Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol. 24(7):849–57. doi:https://doi.org/10.14670/HH-24.849
   Google Scholar
• Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M, Fabbri P. 2002. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 15(2):87–92.
   PubMedGoogle Scholar
• Nikiforidis GC, Tsambaos DG, Karamitsos DS, Koutsojannis CC, Georeiou SV. 1993. Brief communication abnormalities of the auditory brainstem response in vitiligo. Scand Audiol. 22(2):97–100.
   PubMed Web of Science ®Google Scholar
• Paquet P, Piérard GE. 1996. Interleukin-6 and the Skin. Int Arch Allergy Immunol. 109(4):308–17.
   PubMed Web of Science ®Google Scholar
• Pichler R, Sfetsos K, Badics B, Gutenbrunner S, Berg J, Auböck J. 2009. Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+/CD8+ T-cell ratio. Wiener Medizinische Wochenschrift. 159(13–14):337–41.
   PubMedGoogle Scholar
• Poole IC, Das PK, Wijngaard RMJGJ, Bos JD, Westerhof W. 1993. Review of the etiopathomechanism of vitiligo: A convergence theory. Exp Dermatol. 2(4):145–53.
   PubMedGoogle Scholar
• Ramagopalan SV, Dyment DA, Valdar W, Herrera BM, Criscuoli M, Yee IML, Sadovnick AD, Ebers GC. 2007. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol. 6(7):604–10.
   PubMed Web of Science ®Google Scholar
• Rashtak S, Pittelkow MR. 2008. Skin involvement in systemic autoimmune diseases. In: Nickoloff BJ, Nestle FO, editors. Dermatologic Immun. Basel, Switzerland: KARGER; p. 344–58.
   Google Scholar
• Sabate M, Bosch A, Pedros C, Figueras A. 1999. Vitiligo associated with tolcapone and levodopa in a patient with parkinson’s disease. Ann Pharmacother. 33(11):1228–29.
   PubMed Web of Science ®Google Scholar
• Sanceau J, Wijdenes J, Revel M, Wietzerbin J. 1991. IL-6 and IL-6 receptor modulation by IFN-gamma and tumor necrosis factor-alpha in human monocytic cell line (THP-1). Priming effect of IFN-gamma. J Immunol. 147(8):2630–7.
   PubMedGoogle Scholar
• Sehgal V, Srivastava G. 2007. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 73(3):149.
   PubMed Web of Science ®Google Scholar
• Shajil EM, Agrawal D, Vagadia K, Marfatia Y, Begum R. 2006a. Vitiligo: clinical profiles in Vadodara, Gujarat. Indian J Dermatol. 51(2):100–04.
   Google Scholar
• Shajil EM, Chatterjee S, Agrawal D, Bagchi T, Begum R. 2006b. Vitiligo: pathomechanisms and genetic polymorphisms of susceptible genes. Indian J Exp Biol. 44:526–39.
   PubMedGoogle Scholar
• Shajil EM, Laddha NC, Chatterjee S, Gani AR, Malek RA, Shah BJ, Begum R. 2007. Association of catalase T/C exon 9 and glutathione peroxidase codon 200 polymorphisms in relation to their activities and oxidative stress with vitiligo susceptibility in Gujarat population. Pigment Cell Res. 20(5):405–07.
   PubMedGoogle Scholar
• Shi YY, He L. 2005. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15(2):97–98.
   Web of Science ®Google Scholar
• Silverberg NB. 2015. The Epidemiology of Vitiligo. Curr Dermatol Rep. 4(1):36–43.
   Web of Science ®Google Scholar
• Singh A, Sharma P, Kar HK, Sharma VK, Tembhre MK, Gupta S, Laddha NC, Dwivedi M, Begum R, Gokhale RS, et al., . 2012a. HLA alleles and amino acid signatures of the peptide binding pockets of HLA molecules in Vitiligo. J Invest Dermatol. 132(1):124–34. doi:https://doi.org/10.1038/jid.2011.240.
   PubMed Web of Science ®Google Scholar
• Singh M, Kotnis A, Jadeja SD, Mondal A, Mansuri MS, Begum R. 2018a. Cytokines: the yin and yang of vitiligo pathogenesis. Expert Rev Clin Immunol. 15(2):177–88.
   PubMed Web of Science ®Google Scholar
• Singh M, Mansuri MS, Jadeja SD, Marfatia YS, Begum R. 2018b. Association of Interleukin 1 Receptor Antagonist (IL1RN) intron 2 VNTR polymorphism with vitiligo susceptibility in Gujarat population. Ind J Dermatol Venereol Leprol. 84(3):285–91.
   PubMed Web of Science ®Google Scholar
• Singh M, Mansuri MS, Parasrampuria M, Begum R. 2016. Interleukin 1-α: a modulator of melanocyte homeostasis in vitiligo. Biochem Anal Biochem. 5(2):273.
   Google Scholar
• Singh S, Singh U, Pandey S. 2012b. Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients. Indian J Dermatol. 57(1):12.
   PubMedGoogle Scholar
• Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. 1991. Interleukins 1α and 6 and tumor necrosis factor-α are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol. 96(2):180–85.
   PubMed Web of Science ®Google Scholar
• Taïeb A. 2000. Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell Res. 13(SUPPL.8):41–47.
   PubMedGoogle Scholar
• Tanabe O, Akira S, Kamiya T, Wong GG, Hirano T, Kishimoto T. 1988. Genomic structure of the murine IL-6 gene. High degree conservation of potential regulatory sequences between mouse and human. J Immunol. 141(11):3875–81.
   PubMed Web of Science ®Google Scholar
• Tanaka TO, Ogata A, Kishimoto T. 2013. Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update. Rheumatology: Current Research. S4. doi:https://doi.org/10.4172/2161-1149.S4-002
   Google Scholar
• Terry CF, Loukaci V, Green FR. 2000. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 275(24):18138–44.
   PubMed Web of Science ®Google Scholar
• Tu CX, Gu JS, Lin XR. 2003. Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Sci. 31(1):73–78.
   PubMed Web of Science ®Google Scholar
• Turner NA, Mughal RS, Warburton P, O’Regan DJ, Ball SG, Porter KE. 2007. Mechanism of TNFα-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res. 76(1):81–90.
   PubMed Web of Science ®Google Scholar
• Vachtenheim J, Borovanský J. 2010. “Transcription physiology” of pigment formation in melanocytes: central role of MITF. Exp Dermatol. 19(7):617–27.
   PubMed Web of Science ®Google Scholar
• Varoglu AO, Kocatürk I, Tatar A. 2010. Prothrombin G20210A mutation, hypogonadotropic hypogonadism, and generalized vitiligo-related ischemic stroke in a young adult. Int J Neurosci. 120(6):451–53.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu S, Liao J, Zhong L, Xing T, Fan J, Peng Z. 2016. Interleukin-6 and rs1800796 locus single nucleotide polymorphisms in response to hypoxia/reoxygenation in hepatocytes. Int J Mol Med. 38(1):192–200.
   Web of Science ®Google Scholar
• Yacubian EMT, Rosemberg S, Garrido Neto TL, Marie SKN, Valério RMF, Jorge CL. 2001. Rasmussen encephalitis associated with segmental vitiligo of the scalp: clinicopathologic report. J Child Neurol. 16(5):374–77.
   PubMed Web of Science ®Google Scholar
• Yu HS, Chang KL, Yu CL, Li HF, Wu MT, Ching Shuang W, Shuang WC. 1997. Alterations in IL-6, IL-8, GM-CSF, TNF-α, and IFN-γ release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol. 108:527–29.
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Chen JJ, Liu JB. 2005. The genetic concept of vitiligo. J Dermatol Sci. 39(3):137–46.
   PubMed Web of Science ®Google Scholar
• Zhao B, Li X, Li R. 2019. Genetic relationship between IL-6 rs1800796 polymorphism and susceptibility to periodontitis. Immunol Invest. 48(3):268–82.
   PubMed Web of Science ®Google Scholar